We performed a 5-question survey of 40 oncologists from the US and the EU to gauge current prescribing practices for targeted therapies and gauge interest in new drug candidates for the treatment of breast cancer.
Drugs and drug candidates discussed: palbociclib, neratinib, Herceptin, Perjeta, Kadcyla, Tykerb, Afinitor.
Please describe your current usage of HER2-targeted therapies. Of your HER2-positive patients, what percentage
received the following drugs in the last three months? Please consider all HER2-positive patients in all treatment
settings. [free numerical response for each drug]
The combination of the oral EGFR/HER2 inhibitor neratinib + capecitabine is in clinical trials for HER2+ breast
cancer, for patients failing trastuzumab, anthracycline, and taxane regimens.
Please describe your current usage of Afinitor (everolimus) for breast cancer. Of your patients with advanced
HR+/HER2- breast cancer, what percentage received everolimus in the last three months? Please consider only
HR+/HER2- patients with locally advanced or metastatic disease. [free numerical response for each drug]
The CDK 4/6 inhibitor palbociclib is in clinical trials for treatment of ER+/HER2- breast cancer. Assume this drug approved in 2015 based on data from a Phase II trial of palbociclib + letrozole (table below).
How would you rate palbociclib on these factors? (1=worst, 5=best)
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.